NCT01652144View on ClinicalTrials.gov

A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 14, 2012

Primary Completion Date

December 2, 2014

Study Completion Date

February 13, 2015

Conditions
Mantle Cell Lymphoma
Interventions
DRUG

AT7519M

Trial Locations (6)

R3E 0V9

CancerCare Manitoba, Winnipeg

B3H 1V7

QEII Health Sciences Centre, Halifax

L8V 5C2

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton

M5G 2M9

Univ. Health Network-Princess Margaret Hospital, Toronto

H2W 1S6

McGill University - Dept. Oncology, Montreal

S4T 7T1

Allan Blair Cancer Centre, Regina

Sponsors
All Listed Sponsors
collaborator

Astex Pharmaceuticals, Inc.

INDUSTRY

lead

NCIC Clinical Trials Group

NETWORK